Atlanta, GA (PRWEB) November 29, 2011
Aderans Research recently expanded its hair loss clinical trial to four new cities across the United States. With nearly 350 subjects to date, Aderans is undertaking one of the largest clinical studies ever designed to research cell-based solutions to pattern hair loss.
“We continue to make good progress in our research and have a very positive outlook for the trial,” said Chief Executive Officer Ken Washenik, M.D., Ph.D. “Plans are in order to finish Phase 2 next year and we’ll be one step closer to helping those who suffer from male and female pattern hair loss.”
Launched in November 2008, Phase 2 is being conducted in 21 locations across the country. The newest sites to participate in the trial are Santa Rosa, Calif.; Greer, S.C.; Akron, Ohio; and Denver, Colo. Aderans continues to recruit subjects; visit http://www.aderansresearch.com/ari_clinicupdates.html for details about active locations.
“Our cell engineering process is unlike any other,” said Vern Liebmann, Chief Operating Officer. “We’re focused on finding the most promising cell product treatment from the Ji Gami™ family of cell products. We are confident this holds the key to hair restoration.”
A pioneer in its field, Aderans is committed to developing cutting-edge solutions for those who struggle with hair loss. For more information about Aderans Research, visit http://www.aderansresearch.com.
About Aderans Research
Aderans Research is a pioneer in the research and development of safe, effective cell engineered products for hair regeneration. Located in Atlanta, Aderans Research is a subsidiary of Aderans Co., Ltd, the world’s largest wig manufacturer, and affiliate of Bosley, a global leader in surgical hair restoration.
Ongoing information on ARI’s clinical study can be seen at http://aderansresearch.com/ari_clinicalupdates.html.
Additional information on ARI can be found at http://www.aderansresearch.com.
Learn more about ARI’s parent company Aderans Co., Ltd. at http://www.aderans.com/english/index.html.